Stephen Neil Gomperts, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lewy Body Disease | 15 | 2024 | 229 | 4.940 |
Why?
|
| Parkinson Disease | 16 | 2024 | 2775 | 2.600 |
Why?
|
| Amyloid beta-Peptides | 10 | 2023 | 3587 | 1.600 |
Why?
|
| Carbolines | 8 | 2021 | 265 | 1.430 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 3 | 2021 | 422 | 1.340 |
Why?
|
| Hippocampus | 8 | 2022 | 3675 | 1.070 |
Why?
|
| Putamen | 2 | 2021 | 291 | 0.830 |
Why?
|
| Positron-Emission Tomography | 13 | 2021 | 6234 | 0.750 |
Why?
|
| Basal Ganglia Diseases | 1 | 2021 | 149 | 0.740 |
Why?
|
| Neurofilament Proteins | 1 | 2021 | 318 | 0.670 |
Why?
|
| Alzheimer Disease | 10 | 2023 | 8037 | 0.670 |
Why?
|
| Nicotine | 1 | 2024 | 681 | 0.660 |
Why?
|
| Second Messenger Systems | 1 | 2019 | 206 | 0.640 |
Why?
|
| tau Proteins | 5 | 2017 | 1868 | 0.580 |
Why?
|
| Dementia | 5 | 2023 | 2518 | 0.560 |
Why?
|
| Aniline Compounds | 7 | 2019 | 986 | 0.550 |
Why?
|
| Ventral Tegmental Area | 1 | 2015 | 142 | 0.490 |
Why?
|
| Thiazoles | 7 | 2019 | 1483 | 0.470 |
Why?
|
| Brain | 10 | 2023 | 26385 | 0.440 |
Why?
|
| Neocortex | 1 | 2016 | 400 | 0.430 |
Why?
|
| Calcium | 5 | 2023 | 5756 | 0.410 |
Why?
|
| Wakefulness | 1 | 2019 | 1245 | 0.410 |
Why?
|
| Neural Pathways | 2 | 2021 | 2972 | 0.370 |
Why?
|
| Amyloid | 3 | 2019 | 795 | 0.360 |
Why?
|
| Disease Progression | 4 | 2023 | 13284 | 0.300 |
Why?
|
| Cerebral Cortex | 2 | 2021 | 5708 | 0.290 |
Why?
|
| Smoking | 1 | 2024 | 8987 | 0.290 |
Why?
|
| Sleep | 3 | 2023 | 4623 | 0.280 |
Why?
|
| Cognition | 3 | 2013 | 6770 | 0.280 |
Why?
|
| Neurons | 6 | 2019 | 9338 | 0.260 |
Why?
|
| Disease Management | 1 | 2016 | 2459 | 0.260 |
Why?
|
| Radiopharmaceuticals | 4 | 2017 | 2645 | 0.230 |
Why?
|
| Receptors, AMPA | 3 | 2000 | 331 | 0.220 |
Why?
|
| Tauopathies | 2 | 2017 | 307 | 0.210 |
Why?
|
| Cocaine | 2 | 2019 | 1007 | 0.210 |
Why?
|
| Synapses | 3 | 2000 | 1728 | 0.200 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 4 | 2000 | 895 | 0.190 |
Why?
|
| Neuropsychological Tests | 5 | 2017 | 6993 | 0.190 |
Why?
|
| Supranuclear Palsy, Progressive | 2 | 2017 | 77 | 0.180 |
Why?
|
| Glucosylceramidase | 1 | 2020 | 124 | 0.170 |
Why?
|
| Receptors, Glutamate | 1 | 2000 | 232 | 0.170 |
Why?
|
| Action Potentials | 2 | 2019 | 1806 | 0.170 |
Why?
|
| Mice, Transgenic | 4 | 2023 | 9734 | 0.160 |
Why?
|
| Aged | 16 | 2021 | 163280 | 0.150 |
Why?
|
| Microarray Analysis | 2 | 2009 | 767 | 0.140 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2021 | 1107 | 0.130 |
Why?
|
| Autopsy | 1 | 2019 | 1020 | 0.130 |
Why?
|
| Caffeine | 1 | 2020 | 699 | 0.130 |
Why?
|
| REM Sleep Behavior Disorder | 1 | 2016 | 105 | 0.130 |
Why?
|
| Humans | 31 | 2024 | 744343 | 0.130 |
Why?
|
| Middle Aged | 15 | 2021 | 213383 | 0.120 |
Why?
|
| Congresses as Topic | 1 | 2019 | 764 | 0.120 |
Why?
|
| Neurologic Examination | 2 | 2020 | 930 | 0.120 |
Why?
|
| Uric Acid | 1 | 2020 | 766 | 0.120 |
Why?
|
| Male | 18 | 2021 | 350118 | 0.120 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2016 | 257 | 0.110 |
Why?
|
| Mesencephalon | 1 | 2015 | 329 | 0.110 |
Why?
|
| Evoked Potentials | 1 | 1998 | 1056 | 0.110 |
Why?
|
| Female | 17 | 2021 | 380194 | 0.110 |
Why?
|
| Apolipoprotein E3 | 1 | 2012 | 97 | 0.100 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 1782 | 0.100 |
Why?
|
| Autoradiography | 3 | 2017 | 745 | 0.100 |
Why?
|
| Disease Models, Animal | 4 | 2023 | 18029 | 0.100 |
Why?
|
| Levodopa | 1 | 2012 | 219 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2020 | 35421 | 0.100 |
Why?
|
| Radionuclide Imaging | 1 | 2015 | 2031 | 0.100 |
Why?
|
| Carbon Radioisotopes | 1 | 2012 | 577 | 0.100 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2023 | 238 | 0.100 |
Why?
|
| Animals | 14 | 2023 | 168757 | 0.100 |
Why?
|
| Antiparkinson Agents | 1 | 2012 | 184 | 0.100 |
Why?
|
| Electrophysiology | 3 | 2009 | 1308 | 0.090 |
Why?
|
| Rats | 7 | 2015 | 24260 | 0.090 |
Why?
|
| Cross-Sectional Studies | 5 | 2020 | 25043 | 0.090 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 57776 | 0.090 |
Why?
|
| Models, Neurological | 2 | 2013 | 1774 | 0.080 |
Why?
|
| Apolipoprotein E4 | 1 | 2012 | 668 | 0.080 |
Why?
|
| Cholecalciferol | 1 | 2013 | 537 | 0.080 |
Why?
|
| Central Nervous System | 1 | 1996 | 1357 | 0.080 |
Why?
|
| Cognition Disorders | 3 | 2020 | 4043 | 0.080 |
Why?
|
| Microelectrodes | 1 | 2009 | 303 | 0.080 |
Why?
|
| Amyloid beta-Protein Precursor | 2 | 2023 | 1121 | 0.080 |
Why?
|
| Parietal Lobe | 1 | 2012 | 838 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 12959 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 9959 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 13989 | 0.070 |
Why?
|
| Mice | 6 | 2023 | 81183 | 0.070 |
Why?
|
| Contrast Media | 1 | 2019 | 5300 | 0.070 |
Why?
|
| Tissue Distribution | 1 | 2008 | 2327 | 0.060 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 1343 | 0.060 |
Why?
|
| Astrocytes | 2 | 2023 | 1270 | 0.060 |
Why?
|
| Time and Motion Studies | 1 | 2023 | 149 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2019 | 3309 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2015 | 3188 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 7913 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 1 | 1996 | 4462 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 14 | 1 | 2022 | 28 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2015 | 10252 | 0.050 |
Why?
|
| Synaptic Transmission | 2 | 2019 | 1178 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 39050 | 0.050 |
Why?
|
| Entropy | 1 | 2023 | 209 | 0.050 |
Why?
|
| GTP Phosphohydrolases | 2 | 2022 | 509 | 0.050 |
Why?
|
| Movement | 1 | 2008 | 1471 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2000 | 8301 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 21827 | 0.050 |
Why?
|
| Calcium, Dietary | 1 | 2023 | 526 | 0.050 |
Why?
|
| Prognosis | 1 | 2021 | 29063 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2013 | 6196 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 7279 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2015 | 53288 | 0.040 |
Why?
|
| New Orleans | 1 | 2019 | 27 | 0.040 |
Why?
|
| Sleep, REM | 1 | 2023 | 595 | 0.040 |
Why?
|
| Tetrodotoxin | 1 | 2000 | 259 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 1996 | 7880 | 0.040 |
Why?
|
| Postural Balance | 1 | 2023 | 620 | 0.040 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2000 | 377 | 0.040 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2000 | 211 | 0.040 |
Why?
|
| Mutation | 2 | 2020 | 29786 | 0.040 |
Why?
|
| Genotype | 1 | 2012 | 12951 | 0.040 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2019 | 271 | 0.040 |
Why?
|
| Quinoxalines | 1 | 1998 | 290 | 0.040 |
Why?
|
| Diagnosis | 1 | 2017 | 154 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 5535 | 0.040 |
Why?
|
| Radioligand Assay | 1 | 2017 | 374 | 0.040 |
Why?
|
| Tritium | 1 | 2017 | 745 | 0.040 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 1998 | 449 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2016 | 6600 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 1998 | 964 | 0.030 |
Why?
|
| TDP-43 Proteinopathies | 1 | 2015 | 38 | 0.030 |
Why?
|
| Neurotransmitter Agents | 1 | 2019 | 647 | 0.030 |
Why?
|
| Microglia | 1 | 2023 | 1266 | 0.030 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 15540 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2020 | 21746 | 0.030 |
Why?
|
| Plaque, Amyloid | 1 | 2019 | 729 | 0.030 |
Why?
|
| Frontotemporal Lobar Degeneration | 1 | 2015 | 99 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 1999 | 970 | 0.030 |
Why?
|
| Inclusion Bodies | 1 | 2015 | 279 | 0.030 |
Why?
|
| ras Proteins | 1 | 1999 | 1060 | 0.030 |
Why?
|
| Fluorine Radioisotopes | 1 | 2017 | 442 | 0.030 |
Why?
|
| Neuromuscular Junction | 1 | 1996 | 398 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 1998 | 2726 | 0.030 |
Why?
|
| Potassium Channels | 1 | 1996 | 563 | 0.030 |
Why?
|
| Eating | 1 | 2020 | 1536 | 0.030 |
Why?
|
| Atrophy | 1 | 2017 | 1583 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2020 | 2019 | 0.030 |
Why?
|
| Molecular Imaging | 1 | 2019 | 828 | 0.030 |
Why?
|
| Brain Mapping | 2 | 2017 | 6669 | 0.030 |
Why?
|
| Cadaver | 1 | 2015 | 1337 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2019 | 8949 | 0.020 |
Why?
|
| Ion Channels | 1 | 1996 | 1056 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 2703 | 0.020 |
Why?
|
| Intracranial Hemorrhages | 1 | 2015 | 855 | 0.020 |
Why?
|
| Cells, Cultured | 3 | 1999 | 19229 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2022 | 12026 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2023 | 6150 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1996 | 2866 | 0.020 |
Why?
|
| Sex Factors | 1 | 2020 | 10397 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 1996 | 2915 | 0.020 |
Why?
|
| rac GTP-Binding Proteins | 1 | 1999 | 164 | 0.010 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 1999 | 241 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1999 | 599 | 0.010 |
Why?
|
| Prevalence | 1 | 2013 | 15226 | 0.010 |
Why?
|
| Adenoviridae | 1 | 1998 | 1099 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 1999 | 1185 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 1998 | 1224 | 0.010 |
Why?
|
| Cell Division | 1 | 1999 | 4568 | 0.010 |
Why?
|
| Actins | 1 | 1999 | 2121 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1998 | 3420 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1998 | 6622 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 2017 | 77449 | 0.000 |
Why?
|
| Adult | 1 | 2017 | 214055 | 0.000 |
Why?
|
| Signal Transduction | 1 | 1998 | 23403 | 0.000 |
Why?
|